1.
Effect of multidisciplinary health education based on lifestyle medicine on menopausal syndrome and lifestyle behaviors of menopausal women: A clinical controlled study.
Li, Y, He, H, Wang, J, Chen, Y, Wang, C, Li, X, Dai, A, Liu, Y, Xi, X, Huang, J, et al
Frontiers in public health. 2023;:1119352
Abstract
BACKGROUND Menopausal women may experience menopausal syndrome and long-term effects caused by low estrogen levels, such as senile dementia and osteoporosis in the elderly. Most menopausal women may have misconceptions about menopause and low use of pharmacological interventions. These misconceptions may damage the quality of life and miss the critical period for preventing senile diseases. Thus, enhancing the awareness of menopausal women regarding psychosocial and physical changes through health education programs was a way to improve positive attitudes toward menopause and make further treatment options. OBJECTIVES This study aimed to evaluate the effect of multidisciplinary health education based on lifestyle medicine on menopausal syndrome and lifestyle behaviors of menopausal women. METHODS The study was conducted in several hospitals in Chongqing, China. The two groups were from different hospitals with similar medical levels in order to reduce information contamination. It was designed as a clinical controlled trial in which the intervention group (n = 100) and control group (n = 87) were matched for age, age at menarche, menopausal symptoms and drug use status at enrollment. Women in the intervention group received multidisciplinary health education based on lifestyle medicine for 2 months while those in the control group received routine outpatient health guidance. Menopausal syndrome, physical activity and dietary status of participants were assessed before and after the intervention. Paired t-tests and Independent-sample t-tests were adopted for comparison within and between groups, respectively, in the normal variables. Wilcoxon signed-rank tests and Mann-Whitney U tests were adopted for comparison within and between group, respectively, in the abnormal variables. Categorical variables were tested using Pearson's χ2. P-value < 0.05 was statistically significant in statistical tests. RESULTS Post intervention testing indicated that menopausal syndrome of participants was significantly improved in the intervention group compared to the control group (P < 0.001). Between-group comparison showed a significant improvement of weekly energy expenditure of total physical activity (P = 0.001) and participation in exercise (P < 0.001) in the intervention group compared to the control group after the intervention. The dietary status of participants was significantly improved in the intervention group compared to the control group (P < 0.001). In the intervention group, the menopausal syndrome of participants improved more in the hormone drug group than in the non-hormone group (P = 0.007), as did the control group (P = 0.02). In the hormone drug group, the physical activity (P = 0.003) and dietary status (P = 0.001) mproved more in the intervention group than in the control group. CONCLUSIONS The multidisciplinary health education based on lifestyle medicine was effective in improving the menopausal syndrome and healthy lifestyle behaviors of menopausal women. Studies with extended observation period and larger sample size are in need to evaluate the long-term scale-up effects of the multidisciplinary health education.
2.
Pharmacokinetic study of imrecoxib in patients with renal insufficiency.
Pei, Q, Xie, JL, Huang, J, Liu, WY, Yang, XY, Wang, Y, Li, W, Tan, HY, Zhang, H, Yang, GP
European journal of clinical pharmacology. 2019;(10):1355-1360
Abstract
OBJECTIVE Renal insufficiency may influence the pharmacokinetics of drugs. We have investigated the pharmacokinetic parameters of imrecoxib and its two main metabolites in individuals with osteoarthritis (OA) with normal renal function and renal insufficiency, respectively. METHODS This was a prospective, parallel, open, matched-group study in which 24 subjects were enrolled (renal insufficiency group, n = 12; healthy control group, n = 12). Blood samples of subjects administered 100 mg imrecoxib were collected at different time points and analyzed. Plasma concentrations of imrecoxib and its two metabolites (M1 and M2) were determined by the liquid chromatography-tandem mass spectrometry method, and pharmacokinetic parameters (clearance [CL], apparent volume of distribution [Vd], maximum (or peak) serum concentration [Cmax], amount of time drug is present in serum at Cmax [Tmax], area under the curve [AUC; total drug exposure across time], mean residence time [MRT] and elimination half-life [t1/2]) were calculated. RESULTS The demographic characteristics of the two groups were not significantly different, with the exception of renal function. The mean Cmax and AUC0-t (AUC from time 0 to the last measurable concentration) of imrecoxib in the renal insufficiency group were 59 and 70%, respectively, of those of the healthy control volunteers with normal renal function, indicating a significant decline in the former group (P < 0. 05). The mean pharmacokinetic parameters of Ml in the renal insufficiency and healthy control groups did not significantly differ. In contrast, the mean Cmax and AUC0-t of M2 in the renal insufficiency group were 233 and 367%, respectively, of those of the normal renal function group, indicating a significant increase in the former group (P < 0.05). The mean CL/F (clearance/bioavailability) of M2 of the renal insufficiency group was 37% of that of the normal renal function group, indicating a notable reduction in the former group (P < 0.05). CONCLUSION The exposure of imrecoxib in OA patients with renal insufficiency showed a decline compared to that in healthy subjects. However, in patients with renal insufficiency the exposure of M2 was markedly increased and the CL was noticeably reduced. These results indicate that the dosage of imrecoxib should be reduced appropriately in patients with renal insufficiency.
3.
Association of serum resistin with peripheral arterial disease.
Zheng, H, Xu, H, Xie, N, Huang, J, Fang, H, Luo, M
Polskie Archiwum Medycyny Wewnetrznej. 2013;(12):680-5
Abstract
INTRODUCTION Resistin is an inflammatory mediator and a potential biomarker in cardiovascular diseases. OBJECTIVES We sought to examine its association with peripheral arterial disease (PAD). PATIENTS AND METHODS We recruited 200 patients with PAD and 100 healthy controls. Patients were divided into 4 subgroups according to the Fontaine classification for PAD, that is, from Stage I to Stage IV. Serum resistin levels were compared between the PAD group and the control group and among 4 PAD subgroups adjusted for selected factors. RESULTS Serum resistin (Ln‑resistin - log scale) levels and high‑sensitivity C‑reactive protein (hsCRP) levels in patients with PAD were higher than in healthy controls (P <0.05). Moreover, among the 4 PAD subgroups, the value of Ln‑resistin in Stage I subgroup was the lowest, and Stage II subgroup had lower Ln‑resistin than Stage III subgroup or Stage IV subgroup (P <0.05). There was also a significant difference in hsCRP levels among those 4 subgroups (P <0.05). In PAD patients, Ln‑resistin levels correlated inversely with the ankle-brachial pressure index (r = -0.301, P <0.05), and positively with total cholesterol levels (r = 0.228, P <0.01). Moreover, a multivariate analysis showed Ln‑resistin levels to be an independent risk factor for PAD (odds ratio, 1.237; 95% confidence interval, 1.086-1.396; P <0.01). CONCLUSIONS Ln‑resistin levels and hsCRP are elevated in PAD patients, and they rise as the severity of PAD increases. A multivariate analysis suggests that Ln‑resistin could be a prognostic biomarker for the presence of PAD.
4.
[Effect of compound Polygonum multiflorum extract on Alzheimer's disease].
Chen, L, Huang, J, Xue, L
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences. 2010;(6):612-5
Abstract
OBJECTIVE To observe the clinical effect of compound Polygonum multiflorum extract on Alzheimer's disease (AD). METHODS We collected 209 AD patients, among whom 120 were treated with compound Polygonum multiflorum extract as a treatment group, 60 were treated with Polygonum multiflorum extract as a Chinese herb control group, and 29 were treated with Naofukang as a western medicine control group. The scores for the Mini-Mental State Examination (MMSE), Ability of Daily Living Scale (ADL) and the therapeutic effect were assessed and compared before and after the 12 week treatment. RESULTS After the treatment the scores for MMSE and ADL were improved in all groups. The scores of MMSE and ADL in the compound Polygonum multiflorum extract treatment group were significantly improved compared with the Chinese herb control group and the western medicine control group (P < 0.01). The total effective rate of 93.33% in the compound Polygonum multiflorum extract treatment group was better than 73.33% in the Chinese herb control group and 68.97% in the western medicine control group (P < 0.01). CONCLUSION Compound Polygonum multiflorum extract has effect on AD, and it is superior to Polygonum multiflorum extractor Naofukang.